EUVIMEDEUVIMED entdecken
Fallbericht

How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists

Hanny Al-Samkari iD, Gerald A Soff

Blood · 17.09.2026 · 148 (12) · 1534-1546

DOI: 10.1182/blood.2026034099 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Blood, erschienen am 17.09.2026. Verfasst von Hanny Al-Samkari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Receptors, Thrombopoietin, Thrombocytopenia, Thrombopoietin, Recombinant Fusion Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy that may result in major bleeding events and reduction of chemotherapy relative dose intensity. Although there remain no widely available licensed therapies to manage CIT, major studies, including global pivotal phase 3 clinical trials of the thrombopoietin receptor agonists (TPO-RAs) romiplostim and avatrombopag in CIT, have been completed, along with additional supporting evidence from other clinical trials and observational studies. As with patients with chemotherapy-induced neutropenia, not all patients with CIT require treatment, but for those who do, it can have a major impact on a patient’s oncologic care and outcomes. Proper management of CIT requires an understanding of the 2 clinical subtypes of CIT (persistent and nadir), the limited role of platelet transfusions and antifibrinolytics, and when and how to appropriately use TPO-RA support. In this article, 4 patient cases of CIT are used to illustrate common and challenging scenarios occurring in clinical practice. Built on a framework of published studies and supported by extensive clinical experience, appropriate treatment strategies for CIT are described in detail, with emphasis on proper selection of patient, dosing, titration, and monitoring for the use of TPO-RAs in CIT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ThrombopoietinThrombocytopeniaThrombopoietinRecombinant Fusion ProteinsReceptors, FcAntineoplastic AgentsHumansFemaleMaleMiddle AgedAged

Substanzen

Receptors, ThrombopoietinThrombopoietinRecombinant Fusion ProteinsromiplostimReceptors, FcAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Division of Hematology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL.

ORCID-Profile: Hanny Al-Samkari

Zitieren

APA

Al-Samkari, H., & Soff, G. A. (2026). How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists. Blood, 148(12), 1534-1546. https://doi.org/10.1182/blood.2026034099

Vancouver

Al-Samkari H, Soff GA. How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists. Blood. 2026;148(12):1534-1546. doi:10.1182/blood.2026034099

BibTeX
@article{AlSamkari2026,
  author = {Al-Samkari, Hanny and Soff, Gerald A},
  title = {How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {12},
  pages = {1534--1546},
  doi = {10.1182/blood.2026034099}
}
Kostenlos starten →